Dr Sam Goldsmith

Dr. Sam Goldsmith is the Head of Commercialisation of Research and Investments at the Cell and Gene Therapy Catapult (CGT Catapult), a leading UK-based organization dedicated to advancing the cell and gene therapy industry. With a PhD and extensive expertise in biotechnology, Sam leads the commercial team, driving strategic initiatives to bridge scientific research and full-scale commercialization of Advanced Therapy Medicinal Products (ATMPs). He plays a pivotal role in fostering investments, guiding academic researchers and early-stage companies to secure funding, and developing robust commercial strategies. Sam has authored insightful blog posts for the British Society for Gene and Cell Therapy (BSGCT), addressing challenges like overcoming the “valley of death” in therapy development, and frequently speaks at industry events, such as the CGT Catapult Investors Day and panel sessions on workforce growth. Based in the UK, his leadership supports the UK’s position as a global hub for cell and gene therapy innovation, attracting significant investment and accelerating the path to market for transformative therapies.